Joseph J. Vallner

Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA.

Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA.

Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA.

Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA.

Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA.

Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.

Lumera Corp. develops proprietary polymer materials and products for a broad range of applications. The company designs proprietary molecular structures and polymer compounds for a broad range of electro-optic, bioscience, RF and specialty nanotechnology applications. The company also has developed proprietary processes for fabricating such devices. Lumera Corp. is headquartered in Bothell, WA.

Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer.